1. A tumor microenvironment-responsive micelle co-delivered radiosensitizer Dbait and doxorubicin for the collaborative chemo-radiotherapy of glioblastoma
- Author
-
Zhang, Shuyue, Jiao, Xiuxiu, Heger, Michal, Gao, Shen, He, Mei, Xu, Nan, Zhang, Jigang, Zhang, Mingjian, Yu, Yuan, Ding, Baoyue, Ding, Xueying, Afd Pharmaceutics, Sub Membrane Biochemistry & Biophysics, Pharmaceutics, Afd Pharmaceutics, Sub Membrane Biochemistry & Biophysics, and Pharmaceutics
- Subjects
Radiation-Sensitizing Agents ,mic-roenvironment-responsive ,Brain Neoplasms ,Pharmaceutical Science ,General Medicine ,Chemoradiotherapy ,chemo-radiotherapy ,Mice ,targeted nanotherapeutics ,Doxorubicin ,Cell Line, Tumor ,Tumor Microenvironment ,Animals ,Humans ,radiosensitization ,Glioblastoma ,Micelles - Abstract
Glioblastoma is rather recalcitrant to existing therapies and effective interventions are needed. Here we report a novel microenvironment-responsive micellar system (ch-K5(s-s)R8-An) for the co-delivery of the radiosensitizer Dbait and the chemotherapeutic doxorubicin (DOX) to glioblastoma. Accordingly, the ch-K5(s-s)R8-An/(Dbait-DOX) micelles plus radiotherapy (RT) treatment resulted in a high degree of apoptosis and DNA damage, which significantly reduced cell viability and proliferation capacity of U251 cells to 64.0% and 16.3%, respectively. The angiopep-2-modified micelles exhibited substantial accumulation in brain-localized U251 glioblastoma xenografts in mice compared to angiopep-2-lacking micelles. The ch-K5(s-s)R8-An/(Dbait-DOX) + RT treatment group exhibited the smallest tumor size and most profound tumor tissue injury in orthotopic U251 tumors, leading to an increase in median survival time of U251 tumor-bearing mice from 26 days to 56 days. The ch-K5(s-s)R8-An/(Dbait-DOX) micelles can be targeted to brain-localized U251 tumor xenografts and sensitize the tumor to chemotherapy and radiotherapy, thereby overcoming the inherent therapeutic challenges associated with malignant glioblastoma.
- Published
- 2022